CSI Market
Sign In | Register

Regenxbio Inc (RGNX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access RGNX quarterly Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Regenxbio Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-193.88
Depreciation & amortization15.62
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue29.28
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation34.56
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized0.00
Imputed Interest On Related Party Debt-
Available For Sale Securities Gross Realized Gain Loss Net-
Debt Securities Available For Sale Realized Gain Loss-
Imputed Interest Income From Licensing-
Increase Decrease In Contract With Customer Liability-
Increase Decrease In Operating Lease Liabilities-8.63
Increase Decrease In Operating Lease Right Of Use Assets12.90
Income taxes0.00
Realized Investment Gains (Losses), Total-0.06
Increase (Decrease) in Accounts Receivable-7.66
Increase (Decrease) in Accounts Payable, Trade-2.28
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.23
Increase (Decrease) in Customer Advances0.00
Increase (Decrease) in Prepaid Expense-2.86
Other Working Capital-2.95
Other Noncash Income (Expense)0.60
Other net0.00
Payments for (Proceeds from) Other Operating Activities1.17
Discontinued operations0.00
Net Cash flow from Operating Activities-123.96
Investing Activities
Capital Expenditures-2.41
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities319.18
Payments to Acquire Marketable Securities-332.63
Real Estate Investments0.00
Proceeds From Sales Of Marketable Debt Securities-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-15.87
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.37
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-59.56
Proceeds From Issuances Of Common Stock Net Of Underwriting Discounts And Commissions-
Repayments Under Liability Related To Sale Of Future Royalties-
Payments Of Transaction Costs For Sale Of Future Loyalties-
Taxes Paid Related To Net Settlement Of Stock Options-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations59.56
Taxes Paid Related To Net Settlement Of Stock Based Awards-0.63
Offering Expenses Related To At The Market Offering Program-
Expenses Related To At- The- Market Offering Programs-0.36
Proceeds From Issuance Of Royalty Bond And Warrants Net Of Transaction Costs144.49
Repayments Under Royalty Monetization Liabilities Net Of Interest-28.10
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities116.77
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-126.38
Total Cash Flow-23.06
4 historic quarters locked

Sign in to unlock the full Regenxbio Inc cash flow history.

Sign In Create Free Account

About Regenxbio Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-094013

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License